Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
39
SMMT Quote, Financials, Valuation and Earnings
Last price:
$18.38
Seasonality move
:
13.05%
Day range:
$17.94 - $18.53
52-week range:
$15.55 - $36.91
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
21,812.02x
P/B ratio:
71.17x
Volume:
1.3M
Avg. volume:
2.4M
1-year change:
-3.26%
Market cap:
$13.7B
Revenue:
--
EPS (TTM):
-$1.24
Analysts' Opinion
-
Consensus RatingSummit Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 11 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $32.52, Summit Therapeutics, Inc. has an estimated upside of 76.93% from its current price of $18.38.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $12.10 representing 100% downside risk from its current price of $18.38.
Fair Value
-
According to the consensus of 14 analysts, Summit Therapeutics, Inc. has 76.93% upside to fair value with a price target of $32.52 per share.
SMMT vs. S&P 500
-
Over the past 5 trading days, Summit Therapeutics, Inc. has overperformed the S&P 500 by 6.53% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Summit Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Summit Therapeutics, Inc. revenues have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Summit Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Summit Therapeutics, Inc. earnings have been falling on a year-over-year basis for 6 quarters in a row. In the most recent quarter Summit Therapeutics, Inc. reported earnings per share of -$0.31.
Enterprise value:
13.4B
EV / Invested capital:
68.03x
Price / LTM sales:
21,812.02x
EV / EBIT:
--
EV / Revenue:
21,886.50x
PEG ratio (5yr expected):
-0.04x
EV / Free cash flow:
-48.98x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$126K
Return On Assets:
-241.51%
Net Income Margin (TTM):
--
Return On Equity:
-283.98%
Return On Invested Capital:
-274.32%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$2M | -$672K | -$126K | -$20K | -$42K | |
| Operating Income | -$66.3M | -$181.9M | -$935.3M | -$58.1M | -$234.2M | |
| EBITDA | -$64.3M | -$181.2M | -$935.2M | -$58.1M | -$234.2M | |
| Diluted EPS | -$1.58 | -$0.28 | -$1.24 | -$0.08 | -$0.31 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $102.2M | $137.1M | $205M | $490.3M | $246.5M | |
| Total Assets | $128.7M | $155.3M | $218.5M | $502.9M | $261.7M | |
| Current Liabilities | $22.8M | $16.7M | $113.7M | $59M | $64.9M | |
| Total Liabilities | $26.4M | $22.1M | $119.1M | $64.9M | $69.5M | |
| Total Equity | $102.3M | $133.2M | $99.4M | $437.9M | $192.3M | |
| Total Debt | $896K | $3M | $103.9M | $28.7M | $2.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$54.4M | -$113.4M | -$274.1M | -$32.2M | -$95M | |
| Cash From Investing | -$661M | -$220M | $407.4M | -$114.6M | -$1.3M | |
| Cash From Financing | $579M | $417.1M | $14.6M | $212.4M | $34.7M | |
| Free Cash Flow | -$54.5M | -$113.5M | -$274.6M | -$32.3M | -$95.1M | |
SMMT
Sector
Market Cap
$13.7B
$28M
Price % of 52-Week High
49.8%
51.03%
Dividend Yield
0%
0%
Shareholder Yield
-0.11%
-1.54%
1-Year Price Total Return
-3.26%
-17.48%
Beta (5-Year)
-1.523
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$17.64
200-day SMA
Sell
Level
$21.90
Bollinger Bands (100)
Sell
Level
17.19 - 24.07
Chaikin Money Flow
Buy
Level
2.1M
20-day SMA
Buy
Level
$17.80
Relative Strength Index (RSI14)
Buy
Level
54.31
ADX Line
Buy
Level
35.17
Williams %R
Neutral
Level
-31.4424
50-day SMA
Buy
Level
$18.28
MACD (12, 26)
Buy
Level
4.74
25-day Aroon Oscillator
Buy
Level
36
On Balance Volume
Neutral
Level
5.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (164.2599)
Sell
CA Score
(Annual)
Level (-2.3913)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (8.6173)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.
Stock Forecast FAQ
In the current month, SMMT has received 11 Buy ratings 3 Hold ratings, and 0 Sell ratings. The SMMT average analyst price target in the past 3 months is $32.52.
-
Where Will Summit Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Summit Therapeutics, Inc. share price will rise to $32.52 per share over the next 12 months.
-
What Do Analysts Say About Summit Therapeutics, Inc.?
Analysts are divided on their view about Summit Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Summit Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $12.10.
-
What Is Summit Therapeutics, Inc.'s Price Target?
The price target for Summit Therapeutics, Inc. over the next 1-year time period is forecast to be $32.52 according to 14 Wall Street analysts, 11 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is SMMT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Summit Therapeutics, Inc. is a Buy. 11 of 14 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of SMMT?
You can purchase shares of Summit Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Summit Therapeutics, Inc. shares.
-
What Is The Summit Therapeutics, Inc. Share Price Today?
Summit Therapeutics, Inc. was last trading at $18.38 per share. This represents the most recent stock quote for Summit Therapeutics, Inc.. Yesterday, Summit Therapeutics, Inc. closed at $18.38 per share.
-
How To Buy Summit Therapeutics, Inc. Stock Online?
In order to purchase Summit Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get SMMT Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
SMMT
Sector
P/E ratio
--
23.89x
PEG ratio
-0.04x
-0.01x
P/B ratio
71.17x
1.82x
Price / LTM sales
21,812.02x
1.60x
Growth Metrics
SMMT
Sector
Revenue growth
--
4.62%
Earnings growth
-302.84%
10.88%
Revenue (5-year growth)
-100%
6.5%
Earnings forecast
-$0.06
-$0.21
Profitability
SMMT
Sector
Profitability FY 2024
-$89K
$3.5M
Return on invested capital
-274.32%
-31.77%
Return on assets
-241.51%
-27.96%
Return on equity
-283.98%
-37.63%
Earnings Date
Last Earnings Date
Oct
20
Next Earnings Date
Feb
24
Estimated Next Earnings Date
Jan
19
Balance Sheet
SMMT
Sector
Total cash
$238.9M
$26.3M
Short term investments
$307.5M
$25.7M
Total assets
$435.6M
$78M
Long term debt
$2.7M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
